BridgeBio Pharma, Inc. (BBIO) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 194.51M | 154.18M | 120.7M | 110.56M | 116.63M | 5.88M | 2.73M | 2.17M | 211.12M | 1.75M | 4.09M | 1.64M |
| Revenue Growth % | 66.78% | 2521.22% | 4318.01% | 4999.86% | -44.76% | 237.08% | -33.22% | 32.11% | 11461.88% | -6.68% | 1110.36% | -97.77% |
| Cost of Goods Sold | 10.43M | 15.42M | 6.56M | 3.65M | 2.64M | 2.08M | 598K | 598K | 598K | 598K | 598K | 599K |
| COGS % of Revenue | 5.36% | 10% | 5.44% | 3.3% | 2.26% | 35.43% | 21.89% | 27.58% | 0.28% | 34.27% | 14.62% | 36.5% |
| Gross Profit | 184.09M | 138.76M | 114.14M | 106.91M | 113.99M | 3.8M | 2.13M | 1.57M | 210.52M | 1.15M | 3.49M | 1.04M |
| Gross Margin % | 94.64% | 90% | 94.56% | 96.7% | 97.74% | 64.57% | 78.11% | 72.42% | 99.72% | 65.73% | 85.38% | 63.5% |
| Gross Profit Growth % | 61.49% | 3553.55% | 5248.5% | 6709.68% | -45.85% | 231.12% | -38.91% | 50.67% | 17816.77% | -6.21% | 971.07% | -98.57% |
| Operating Expenses | 290.05M | 324M | 259.34M | 241.19M | 218.37M | 229.82M | 193.88M | 177.11M | 210.18M | 178.56M | 161.19M | 147.14M |
| OpEx % of Revenue | 149.11% | 210.14% | 214.86% | 218.14% | 187.22% | 3907.26% | 7096.78% | 8169.23% | 99.55% | 10232.84% | 3939.99% | 8966.54% |
| Selling, General & Admin | 163.9M | 182M | 137.62M | 129.15M | 106.36M | 94.78M | 68.82M | 59.52M | 65.81M | 47.58M | 35.78M | 36.12M |
| SG&A % of Revenue | 84.26% | 118.04% | 114.02% | 116.81% | 91.2% | 1611.39% | 2519% | 2745.53% | 31.17% | 2726.82% | 874.53% | 2201.22% |
| Research & Development | 126.64M | 142M | 112.87M | 111.23M | 111.43M | 130.35M | 120.44M | 114.69M | 140.97M | 130.23M | 125.14M | 107.49M |
| R&D % of Revenue | 65.1% | 92.1% | 93.52% | 100.6% | 95.54% | 2216.08% | 4408.64% | 5290.36% | 66.77% | 7462.81% | 3058.81% | 6550.15% |
| Other Operating Expenses | -486K | 0 | 1000K | 805K | 570K | 1000K | 1000K | 1000K | 1000K | 754K | 272K | 1000K |
| Operating Income | -105.96M | -185.24M | -145.2M | -134.28M | -104.37M | -226.03M | -191.75M | -175.54M | 343K | -177.42M | -157.69M | -146.1M |
| Operating Margin % | -54.47% | -120.14% | -120.3% | -121.45% | -89.49% | -3842.69% | -7018.67% | -8096.82% | 0.16% | -10167.11% | -3854.61% | -8903.05% |
| Operating Income Growth % | -1.52% | 18.05% | 24.28% | 23.51% | -30529.15% | -27.4% | -21.6% | -20.15% | 100.27% | -37.28% | -22.13% | -82.22% |
| EBITDA | -104.77M | -180.24M | -143.8M | -132.96M | -103.09M | -224.66M | -190.21M | -173.97M | 1.94M | -175.83M | -156.05M | -144.46M |
| EBITDA Margin % | -53.86% | -116.9% | -119.14% | -120.26% | -88.39% | -3819.45% | -6962.37% | -8024.22% | 0.92% | -10076.28% | -3814.54% | -8803.29% |
| EBITDA Growth % | -1.63% | 19.77% | 24.4% | 23.57% | -5416.55% | -27.77% | -21.89% | -20.42% | 101.56% | -37.83% | -22.42% | -83.81% |
| D&A (Non-Cash Add-back) | 1.19M | 5M | 1.4M | 1.32M | 1.28M | 1.37M | 1.54M | 1.57M | 1.6M | 1.58M | 1.64M | 1.64M |
| EBIT | -105.96M | -185.24M | -174.74M | -144.02M | -127.47M | -236.41M | -141.19M | -52.61M | -12.69M | -150.06M | -159.18M | -140.11M |
| Net Interest Income | -46.57M | -7.67M | -5.5M | -33.74M | -36.76M | -25.14M | -19.77M | -17.74M | -19.4M | -14.69M | -16.51M | -16.08M |
| Interest Income | 6.25M | 4.33M | 6.24M | 3.9M | 5.38M | 4.68M | 3.3M | 5.2M | 4.08M | 5.58M | 3.79M | 4.51M |
| Interest Expense | 52.81M | 12M | 11.74M | 37.64M | 42.14M | 29.82M | 23.06M | 22.94M | 23.47M | 20.27M | 20.31M | 20.59M |
| Other Income/Expense | -60.6M | -12M | -41.28M | -47.38M | -65.24M | -40.21M | 27.5M | 100M | -36.5M | 7.09M | -21.8M | -14.6M |
| Pretax Income | -166.56M | -197.24M | -186.48M | -181.66M | -169.61M | -266.24M | -164.25M | -75.54M | -36.16M | -170.33M | -179.49M | -160.7M |
| Pretax Margin % | -85.63% | -127.93% | -154.5% | -164.3% | -145.42% | -4526.28% | -6012.23% | -3484.5% | -17.13% | -9760.92% | -4387.39% | -9792.99% |
| Income Tax | 0 | 0 | -1.54M | 2.1M | 0 | 1.15M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0.83% | -1.16% | 0% | -0.43% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -164.04M | -197.24M | -182.74M | -181.9M | -167.42M | -265.05M | -162.04M | -73.46M | -35.22M | -168.15M | -177M | -157.9M |
| Net Margin % | -84.33% | -127.93% | -151.4% | -164.52% | -143.55% | -4506.12% | -5931.19% | -3388.19% | -16.68% | -9635.99% | -4326.55% | -9622.12% |
| Net Income Growth % | 2.02% | 25.58% | -12.78% | -147.64% | -375.41% | -57.63% | 8.45% | 53.48% | 74.87% | -22.21% | -28.88% | -1502.06% |
| Net Income (Continuing) | -166.56M | -197.24M | -184.94M | -183.76M | -169.61M | -267.39M | -164.25M | -75.54M | -36.16M | -170.33M | -179.49M | -160.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -951K | -570K | 10.34M | 9.44M | 9.73M | 10.29M | 11.53M | 10.83M | 12.67M | 11.72M | 13.81M | 12.38M |
| EPS (Diluted) | -0.84 | -1.00 | -0.96 | -0.95 | -0.88 | -1.40 | -0.86 | -0.39 | -0.20 | -0.96 | -1.08 | -0.98 |
| EPS Growth % | 4.55% | 28.57% | -11.63% | -143.59% | -340% | -45.83% | 20.37% | 60.2% | 78.26% | 7.69% | -8% | -1358.33% |
| EPS (Basic) | -0.84 | -1.00 | -0.96 | -0.95 | -0.88 | -1.40 | -0.86 | -0.39 | -0.20 | -0.96 | -1.08 | -0.98 |
| Diluted Shares Outstanding | 194.79M | 197.24M | 190.52M | 190.52M | 190.15M | 189.44M | 188.51M | 187.59M | 178.71M | 174.46M | 163.31M | 160.54M |
| Basic Shares Outstanding | 194.79M | 197.24M | 190.52M | 190.52M | 190.15M | 189.44M | 188.51M | 187.59M | 178.71M | 174.46M | 163.31M | 160.54M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |